🟢 Strong Evidence
- Burden of P. vivax recurrence and the case for dose optimisation
- Evidence from meta-analysis: halving recurrence, raising adverse event risk
- Clinical implementation barriers and opportunities in endemic regions
- Integration with broader malaria elimination goals and future research
- Frequently asked questions
A systematic review and individual patient data meta-analysis published in The Lancet Regional Health – Western Pacific found that a total dose of 7 mg/kg primaquine halved the rate of recurrent Plasmodium vivax malaria over a 6-month follow-up period compared with the standard low dose of 3.5 mg/kg across multiple transmission settings in Indonesia. The finding offers a potential strategy to improve cure rates, but comes with a cost: increased daily doses raised the risk of gastrointestinal discomfort and haemolysis in some patients, requiring careful patient selection and monitoring.
Key takeaways
- A cumulative dose of 7 mg/kg primaquine reduced recurrent P. vivax malaria by 50% compared with 3.5 mg/kg over 6 months in Indonesia
- Higher doses increased adverse effects, particularly gastrointestinal symptoms and haemolysis, necessitating patient screening before treatment
- The findings emerge from a robust meta-analysis of individual patient data across diverse transmission zones, strengthening evidence for dose optimisation in endemic regions
Study at a Glance
| Source | The Lancet Regional Health – Western Pacific |
| Study type | Systematic review with individual patient data meta-analysis |
| Population | Patients with P. vivax malaria in Indonesia |
| Interventions compared | 7 mg/kg vs 3.5 mg/kg cumulative primaquine dose |
| Primary outcome | Recurrent P. vivax malaria at 6 months |
Primaquine dose efficacy and safety trade-off in P. vivax treatment
Recurrence rates and adverse event incidence by cumulative dose, Indonesia meta-analysis
Source: The Lancet Regional Health – Western Pacific, 2026 | Georgian Medical Journal News
Burden of P. vivax recurrence and the case for dose optimisation
Plasmodium vivax malaria remains a major public health challenge in Indonesia, with persistent relapses driven by dormant parasites in the liver (hypnozoites). Primaquine is the only widely available drug that eliminates these dormant forms, offering the potential for true radical cure. However, the standard low dose of 3.5 mg/kg, historically chosen to minimise toxicity, has proven insufficient to prevent recurrence, particularly in high-transmission areas. This leaves patients at risk of repeated infections, perpetuating both individual morbidity and ongoing community transmission.
The research team undertook a comprehensive systematic review and individual patient data meta-analysis to assess whether a doubling of the cumulative dose could improve cure rates without becoming unmanageable in resource-constrained settings. By pooling granular patient-level data across Indonesian study cohorts spanning diverse epidemiological zones, the analysis provided robust evidence for dose-related efficacy trends and safety thresholds.
Evidence from meta-analysis: halving recurrence, raising adverse event risk
According to The Lancet Regional Health – Western Pacific meta-analysis, the 7 mg/kg cumulative dose regimen reduced the proportion of patients experiencing recurrent P. vivax malaria within 6 months by approximately 50% compared with the 3.5 mg/kg standard dose. This efficacy advantage was consistent across all transmission settings examined in Indonesia, from low to high endemic zones, demonstrating generalisable benefit across ecological contexts.
The trade-off, however, was quantifiable and clinically significant. Patients receiving the higher dose reported elevated rates of gastrointestinal discomfort—including nausea, vomiting, and abdominal pain—and showed evidence of increased haemolysis (red blood cell breakdown), a particular concern in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic variant in Southeast Asian populations. The meta-analysis emphasises that G6PD screening becomes mandatory before initiating higher-dose primaquine, as undetected deficiency can result in severe, life-threatening haemolytic anaemia.
A cumulative dose of 7 mg/kg primaquine halved recurrent P. vivax malaria rates over 6 months compared with 3.5 mg/kg, but increased gastrointestinal and haemolytic adverse effects in Indonesian populations.
— The Lancet Regional Health – Western Pacific Meta-Analysis Group (2026)
Clinical implementation barriers and opportunities in endemic regions
The findings present a classic clinical dilemma: superior efficacy paired with heightened safety concerns. In Clinical Updates across Southeast Asia, malaria programmes must weigh the public health benefit of preventing recurrence—which reduces onward transmission and hospitalisation—against the logistical and resource demands of rapid G6PD testing, patient counselling on gastrointestinal tolerance, and close clinical monitoring. Many Indonesian healthcare facilities, particularly in rural endemic areas, currently lack access to point-of-care G6PD diagnostics, a critical barrier to safer deployment of higher-dose regimens.
The meta-analysis was conducted across multiple Indonesian transmission settings, from the high-endemic eastern regions (Papua, Nusa Tenggara) to lower-transmission central areas. This geographical diversity strengthens the generalisability of findings within Indonesia but also underscores the heterogeneity of health system capacity. Implementation of a higher-dose primaquine strategy will require investment in diagnostic infrastructure, clinical training, and patient education—resources that are often scarce in the very regions where P. vivax burden is highest.
A practical pathway forward may involve risk stratification: reserving the higher 7 mg/kg dose for high-risk groups (high-transmission zones, young adults, repeat infections) with confirmed G6PD sufficiency, while continuing the lower dose in lower-risk populations or those with borderline G6PD status. Such an approach would maximise population benefit whilst minimising preventable harm, though it demands robust laboratory infrastructure and clinical protocols to operationalise safely.
Integration with broader malaria elimination goals and future research
The World Health Organization and national malaria control programmes in endemic countries have set aggressive Global Health targets for P. vivax elimination in the coming decade. Every reduction in recurrence rates translates directly to fewer relapses, lower transmission pressure, and accelerated progress toward elimination. By demonstrating that a feasible dose adjustment can cut recurrence by half, this meta-analysis provides a practical evidence base for revised treatment guidelines—if implementation barriers can be overcome.
Future research should focus on optimising the dose-safety-efficacy triangle further. Questions remain about whether even higher doses might offer additional efficacy gains, whether modified dosing schedules (fewer, larger daily doses versus divided doses) could improve tolerability, and whether newer alternative drugs targeting hypnozoites might eventually supersede primaquine in high-burden settings. In the interim, the evidence from this rigorous Indonesian meta-analysis argues for G6PD screening as a non-negotiable prerequisite and careful patient selection as the pathway to safer, more effective P. vivax treatment.
What this means
Frequently asked questions
What is the difference between low-dose and high-dose primaquine for P. vivax?
The standard low dose (3.5 mg/kg total) is given at lower daily doses to reduce side effects but leaves many patients with dormant liver parasites that reactivate, causing relapse. The higher dose (7 mg/kg) doubles the total amount, killing more hypnozoites and halving recurrence risk according to The Lancet meta-analysis. The trade-off is increased gastrointestinal and haemolytic side effects in some patients.
Why is G6PD testing critical before higher-dose primaquine?
Primaquine causes red blood cell breakdown in people with G6PD deficiency, a genetic enzyme disorder common in malaria-endemic regions including Indonesia. Without screening, patients could develop severe, potentially life-threatening anaemia. G6PD testing is thus a mandatory safety gate before higher-dose regimens.
What are the main side effects of higher-dose primaquine?
The meta-analysis found that patients on 7 mg/kg experienced elevated rates of nausea, vomiting, abdominal pain, and haemolysis compared with lower doses. Most gastrointestinal symptoms are mild and manageable with food or anti-emetics, but haemolysis in G6PD-deficient individuals can be severe. This is why pre-treatment screening and close monitoring are essential.
As malaria control programmes across Southeast Asia intensify efforts toward regional elimination, evidence on optimised primaquine dosing becomes increasingly valuable. This Indonesian meta-analysis demonstrates that dose escalation is both feasible and effective—but success depends on building diagnostic capacity and embedding G6PD screening into routine malaria care. The path forward is not simply to treat all patients with higher-dose primaquine, but to use this evidence intelligently, matching dose to individual safety profiles and ecological context. With these safeguards in place, higher-dose primaquine can become a cornerstone of Indonesia’s malaria elimination strategy, reducing relapse and transmission whilst protecting vulnerable patient populations.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
